Ipamorelin: Mechanism of Action, Evidence & Applications
Complete scientific guide to Ipamorelin: GHS-R1a mechanism, differences vs other GHRPs, published studies and applications described in literature. Evidence-based content for healthcare professionals.
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Mechanism of Action
Ipamorelin is a growth hormone secretagogue (GHS) pentapeptide that selectively acts on GHSR-1a receptors in the anterior pituitary. Studies demonstrate it stimulates pulsatile GH release without significantly increasing cortisol or prolactin, differentiating it from other secretagogues such as GHRP-6 and GHRP-2.
Data based on available scientific literature. Protocol individualization depends on qualified professional assessment.
Applications Described in the Literature
- ✓Stimulation of endogenous GH secretion documented in animal and human models
- ✓Studies in body composition and age-related sarcopenia
- ✓Research in post-surgical recovery and tissue repair
- ✓Investigations on lipid metabolism and fat redistribution
- ✓Long-term safety studies with favorable adverse effect profile
Relevant Studies
Ipamorelin, the first selective growth hormone secretagogue
1998 · PMID: 9849822
Growth hormone secretagogues: history, mechanism of action, and clinical development
2011 · PMID: 21985178
Selective GH secretagogues and their effects on GH pulse pattern and IGF-1 levels
1999 · PMID: 10416292
Premium
✓ DesbloqueadoProtocols Described in the Literature
Protocols described in the literature use Ipamorelin in specific circadian rhythm windows to maximize endogenous secretory response. Studies demonstrate that administration before sleep coincides with the physiological GH peak, potentiating the secretagogue effect. Combined protocols with GHRH analogues such as CJC-1295 are widely documented, targeting synergistic action at both regulatory points of the GH pathway.
Dose Ranges Observed in Studies
- ◆Ranges observed in studies vary between 100–300 mcg per administration
- ◆Clinical studies use frequencies of 1–3 times daily in GH deficit models
- ◆Duration in reference studies: 8–16 weeks with periodic IGF-1 assessments
- ◆Studies in elderly subjects document doses in the lower range with preserved secretory response
Effects Timeline (Literature)
Studies report improved sleep quality in the first 2–4 weeks. Changes in body composition (fat reduction, lean mass increase) documented between 8–16 weeks. IGF-1 elevations observable from 4–6 weeks of continuous use in controlled studies.
Documented Associations
- ↗CJC-1295 (with or without DAC): widely documented association, acting at complementary points of the GH-IGF-1 axis
- ↗Exogenous GHRH: synergistic mechanism described in maximal stimulation models
- ↗Tesamorelin: documented alternative in lipodystrophy-associated contexts
Monitoring Described in Studies
- ⊕Serum IGF-1: primary marker of GH axis response in follow-up studies
- ⊕Basal and post-stimulation serum GH: described in research protocols
- ⊕Fasting blood glucose: relevant monitoring given GH antagonism to insulin
- ⊕Body composition assessment: DXA documented in 12+ week studies
Clinical Observations from Studies
- ℹFavorable safety profile compared to GHRP-6: no significant increase in ghrelin, cortisol, or prolactin
- ℹNo tachyphylaxis documented in prolonged use studies up to 12 weeks
- ℹCombination studies with GHRH demonstrate additive, not merely summative effect
All information above is exclusively educational, based on scientific literature. It does not constitute medical prescription. Individualization of any protocol requires evaluation by a qualified healthcare professional.
Frequently Asked Questions
What is Ipamorelin?▼
Ipamorelin is a synthetic pentapeptide of the growth hormone secretagogue (GHRP) class, which stimulates GH release via the GHS-R1a receptor in the pituitary, with high selectivity and minimal effect on ACTH and cortisol.
What is the difference between Ipamorelin and GHRP-6?▼
According to comparative studies, Ipamorelin shows greater selectivity for GH pathway, with less stimulation of ACTH, prolactin and cortisol compared to GHRP-6, as described by Raun et al. (1998).
⚠️ Medical Disclaimer: The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.